What Health Canada’s New Prebiotic Monograph Means for Your NHP

Health Canada has published its first prebiotic monograph, providing long-awaited regulatory clarity for natural health products containing prebiotic ingredients. If you manufacture, formulate, or plan to market a prebiotic NHP in Canada, this development could significantly impact your regulatory strategy.

Released on April 24, 2026, by the Natural and Non-prescription Health Products Directorate (NNHPD), the monograph provides a standardized framework for Product Licence Applications (PLAs) covering prebiotic ingredients. For industry stakeholders who have been waiting for regulatory clarity in this space, the wait is over.

Understanding what the prebiotic monograph covers and how to apply it correctly is critical before you move forward with a new submission or update an existing product. The requirements touch everything from permitted ingredients and dosage ranges to the exact health claims your label can carry.  

Getting any of these elements wrong can delay your NPN approval or, worse, trigger a compliance issue after your product is already on market. 

Which Prebiotic Ingredients Are Covered 

The prebiotic monograph covers eight medicinal ingredients:

• Acacia (gum arabic)
• Fructooligosaccharides (FOS)
• Short-chain fructooligosaccharides (scFOS), Inulin
• Transgalactooligosaccharides (GOS)
• Xylooligosaccharides (XOS)
• 2′-Fucosyllactose
• Lacto-N-neotetraose

Each ingredient is defined with proper names, common names, and source information, including the specific plant species and plant parts recognized by Health Canada, where applicable. 

This is not a catch-all for any ingredient a brand might position as a prebiotic. If your ingredient is not on this list, the monograph does not apply, and you will need to submit supporting evidence through a Class III application pathway. 

Knowing which category your product falls into before you start building your submission is the kind of foundational step that saves significant time downstream. 

Prebiotic Claims vs. Fibre Claims: An Important Distinction 

One important aspect of Health Canada’s prebiotic monograph is the clear distinction between prebiotic claims and fibre-content claims. Some ingredients included in the monograph, such as Inulin and Acacia, may be eligible for both prebiotic and fibre-related claims. Health Canada specifically addresses this scenario in the monograph, noting that claims from Tables 2.2 and 2.3 may be combined. However, it recommends keeping claims from Table 2.1 separate from the other claim types to help avoid misinterpretation or unintended links between the different effects being communicated.

For manufacturers, this creates an important labeling consideration. While a product may qualify for multiple claim types, careful attention should be paid to how those claims are presented on the label. Claim placement, grouping, and overall context can all influence how the product’s effects are interpreted by both consumers and regulators.

Although this may seem like a minor detail, it is the type of issue that can generate questions during application review or result in requests for label revisions. Taking the time to structure claims appropriately from the outset can help streamline the licensing process and reduce the likelihood of avoidable regulatory feedback.

Dosage Ranges and Health Claims That Apply 

The monograph organizes permitted claims into three categories. Table 2.1 covers prebiotic and bacterial growth claims, Table 2.2 covers fibre and digestive health claims, and Table 2.3 addresses constipation and irregularity relief. Each claim type is tied to specific medicinal ingredients and daily dose ranges.

For example, Inulin sourced from chicory root or Jerusalem artichoke supports a prebiotic claim at 5 to 15 grams per day, while Acacia requires 10 to 20 grams per day for the same claim. Xylooligosaccharides (XOS) supports a prebiotic and digestive health claim at a range of 1.4 to 8 grams per day, which is notably lower than other ingredients. For constipation relief claims, only Inulin and FOS or scFOS are eligible, and at higher minimum daily doses.

If your formulation includes more than one prebiotic ingredient from the monograph, combination rules apply relating to dosage limitations. The combined daily total must not exceed 15 grams, and XOS specifically must not exceed 8 grams per day regardless of the combination. Understanding how these rules apply with your product’s formula is is critical as it directly affects claim eligibility for your label.

Labelling and Directions for Use 

The prebiotics monograph also specifiesmandatory directions for use that must appear on your label, if it is eligible. In most cases, labels are required to instruct consumers to take the product with at least 250 mL of liquid and to maintain adequate fluid intake. For powder formats, an additional direction is required to mix the product in liquid immediately before consumption.

Certain ingredients and dose levels trigger additional mandatory statements. For example, products containing Inulin or FOS at 5 grams or more per daymust also include a known adverse reaction statement indicating that users may experience temporary gas and bloating. These statements are required as part of the labelling conditions and are not optional..

Products containing Inulin intended for constipation relief require additional cautionionary statements, including consulting a healthcare practitioner if symptoms persistand a contraindication for users with fever or undiagnosed gastrointestinal conditions.

Duration of use restrictions also apply for certain ingredients at specified dose thresholds. For example, Acacia at doses above 10 grams per day requires a direction to seek practitioner guidance for use beyond 12 weeks. XOS at doses above 4 grams per day require similar guidance for use beyond 3 weeks. These requirements are directly linked to ingredient selection and dosage, and they must be reflected accurately on product labels to ensure compliance with the monograph conditions for market authorization.

Class II vs. Class III Applications and Combination Restrictions 

Not every prebiotic formulation qualifies as a Class II application under this monograph. Certain ingredient combinations automatically require a Class III application with supporting evidence.  

These restricted combinations include Inulin or FOS with invertase, GOS with lactase or alpha-galactosidase, XOS with hemicellulase or xylanase, 2′-Fucosyllactose or Lacto-N-neotetraose with lactase, and Acacia with any digestive enzymes. 

If your product includes any of these pairings, planning for a Class III submission from the start will help prevent delays or reclassification later in the review process.

Key Takeaways 

• Health Canada’s new prebiotic monograph covers eight specific medicinal ingredients, each with defined sources, dosage ranges, and permitted health claims.
• Prebiotic claims and fibre-content claims are distinct and should be kept separate on your product label to avoid misinterpretation.
• Combination rules limit total daily prebiotic doses to 15 grams and impose specific caps on XOS; certain ingredient pairings require a Class III application.
• Label requirements include mandatory directions for use, known adverse reactions for where applicable, and duration of use restrictions for select ingredients, such as Acacia and XOS.
• Products not covered by the monograph or falling outside Class II criteria will need evidence-based submissions through the Class III pathway.